Susquehanna Fundamental Investments’s Entera Bio ENTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,200	Closed	-$29K	–	1572
2021 Q4	$29K	Sell	10,200 -4,200	-29%	-$15.7K	﹤0.01%	1387
2021 Q3	$68K	Hold	14,400	–	–	﹤0.01%	1646
2021 Q2	$86K	Buy	+14,400	New	+$53.2K	﹤0.01%	1582

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AWM

Altium Wealth Management Purchase, New York $1.39B AUM 12.44% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Susquehanna Fundamental Investments's ENTX Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Entera Bio (ENTX) in Q1 2022, closing a stake of 10,200 shares — an estimated $29K sold.

Susquehanna Fundamental Investments first reported a position in ENTX in Q2 2021 and held it in 3 quarters. The position peaked at $86K in Q2 2021. 12 funds tracked by Wall St. Rank hold ENTX as of Q1 2022.

Susquehanna Fundamental Investments reported no remaining Entera Bio position as of Q1 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 10,200 Entera Bio shares in Q1 2022, an estimated $29K.
Susquehanna Fundamental Investments first reported a position in Entera Bio in Q2 2021 and held it in 3 quarters.
Susquehanna Fundamental Investments's Entera Bio position peaked at $86K in Q2 2021.
12 funds tracked by Wall St. Rank held Entera Bio as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.